id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-0533-0007,FDA,FDA-2016-E-0533,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-07-29T04:00:00Z,2018,7,2018-07-29T04:00:00Z,,2018-07-29T04:46:11Z,,0,0,09000064835733c5
FDA-2016-E-0533-0006,FDA,FDA-2016-E-0533,"Determination of Regulatory Review Period for Purposes of Patent
Extension; RAPIVAB",Notice,Determinations,2017-11-28T05:00:00Z,2017,11,2017-11-28T05:00:00Z,2018-01-30T04:59:59Z,2017-11-28T16:07:34Z,2017-25676,0,0,0900006482cb8369
FDA-2016-E-0533-0005,FDA,FDA-2016-E-0533,Letter from U.S. Patent and Trademark Office to CDER,Other,Letter(s),2017-07-24T04:00:00Z,2017,7,2017-07-24T04:00:00Z,,2017-07-24T20:56:24Z,,0,0,090000648295e070
FDA-2016-E-0533-0004,FDA,FDA-2016-E-0533,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2017-07-12T04:00:00Z,2017,7,2017-07-12T04:00:00Z,,2017-07-12T21:00:59Z,,0,0,09000064829145aa
FDA-2016-E-0533-0003,FDA,FDA-2016-E-0533,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-05-02T04:00:00Z,2016,5,2016-05-02T04:00:00Z,,2016-05-02T22:24:04Z,,0,0,0900006481fa10f6
FDA-2016-E-0533-0001,FDA,FDA-2016-E-0533,Patent Extension Application from Frommer Lawrence & Haug LLP (on behalf of BioCryst Pharmaceuticals Inc.),Other,Application,2016-02-16T05:00:00Z,2016,2,2016-02-16T05:00:00Z,,2016-02-16T16:15:12Z,,0,0,0900006481e61274
FDA-2016-E-0533-0002,FDA,FDA-2016-E-0533,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2016-02-16T05:00:00Z,2016,2,2016-02-16T05:00:00Z,,2016-02-16T16:16:58Z,,0,0,0900006481e60fbd